Innate Pharma（IPH）株式概要
Innate Pharma S.A.は、フランス国内および国際的にがん患者のための免疫療法を開発するバイオテクノロジー企業として事業を展開している。 詳細
IPH Community Fair Values
Create NarrativeSee what 9 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Innate Pharma S.A. 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | €1.96 |
| 52週高値 | €2.20 |
| 52週安値 | €1.03 |
| ベータ | 0.81 |
| 1ヶ月の変化 | 50.77% |
| 3ヶ月変化 | 35.55% |
| 1年変化 | 0.41% |
| 3年間の変化 | -27.00% |
| 5年間の変化 | -38.01% |
| IPOからの変化 | -59.42% |
最新ニュース
ナラティブの更新 • May 11
IPH: 2026 Oncology Catalysts Will Drive Reassessment Of Risk Reward Profile
Analysts have lifted their price target on Innate Pharma to €8, citing a recalibrated risk profile, a slightly lower discount rate and updated expectations around revenue growth, profit margins and future P/E in light of what they describe as a crucial catalyst stretch for the company’s oncology pipeline through 2026. Analyst Commentary Analysts highlight that the updated €8 price target is closely linked to what they describe as a tight catalyst timeline through 2026.ナラティブの更新 • Apr 24
IPH: 2026 Oncology Readouts Will Define Upside Potential For This Catalyst Story
Narrative update overview Analysts have maintained a €4.50 price target for Innate Pharma, citing updated assumptions on discount rate, revenue, profit margins and future P/E, alongside upcoming 2026 oncology catalysts highlighted in recent Street research. Analyst Commentary Recent Street research frames Innate Pharma as a high-risk, event driven story into 2026, with attention centered on three oncology programs that analysts see as key to justifying current valuation assumptions.Recent updates
ナラティブの更新 • May 11
IPH: 2026 Oncology Catalysts Will Drive Reassessment Of Risk Reward Profile
Analysts have lifted their price target on Innate Pharma to €8, citing a recalibrated risk profile, a slightly lower discount rate and updated expectations around revenue growth, profit margins and future P/E in light of what they describe as a crucial catalyst stretch for the company’s oncology pipeline through 2026. Analyst Commentary Analysts highlight that the updated €8 price target is closely linked to what they describe as a tight catalyst timeline through 2026.ナラティブの更新 • Apr 24
IPH: 2026 Oncology Readouts Will Define Upside Potential For This Catalyst Story
Narrative update overview Analysts have maintained a €4.50 price target for Innate Pharma, citing updated assumptions on discount rate, revenue, profit margins and future P/E, alongside upcoming 2026 oncology catalysts highlighted in recent Street research. Analyst Commentary Recent Street research frames Innate Pharma as a high-risk, event driven story into 2026, with attention centered on three oncology programs that analysts see as key to justifying current valuation assumptions.ナラティブの更新 • Apr 09
IPH: Crucial 2026 Oncology Catalysts Are Expected To Unlock Long Term Upside
Analysts have trimmed their fair value estimate for Innate Pharma from about €6.10 to roughly €4.50, citing a reset in revenue growth expectations and a much higher assumed future P/E multiple, while also highlighting upcoming 2026 oncology catalysts as key to the story. Analyst Commentary Recent research has framed 2026 as an important test for Innate Pharma, with several oncology readouts and milestones clustered into what has been described as a crucial catalyst stretch.分析記事 • Mar 29
Earnings Update: Innate Pharma S.A. (EPA:IPH) Just Reported And Analysts Are Boosting Their Estimates
Investors in Innate Pharma S.A. ( EPA:IPH ) had a good week, as its shares rose 2.4% to close at €1.10 following the...
ナラティブの更新 • Mar 25
IPH: 2026 Oncology Catalysts Are Expected To Support Higher Future Multiple
Analysts have raised their price target on Innate Pharma to €8, citing a refreshed view of the company’s 2026 oncology catalyst lineup, including upcoming monalizumab PACIFIC-9 topline data, IPH4502 Phase 1 readout in solid tumors, and potential Phase 3 initiation for lacutamab pending financing. Analyst Commentary Recent commentary frames Innate Pharma as entering what some bullish analysts describe as a crucial catalyst stretch in 2026, with three oncology programs all lined up for key clinical events.ナラティブの更新 • Mar 11
IPH: Higher Margin Outlook Will Support Higher Future Earnings Multiple
Analysts have adjusted their price target on Innate Pharma, reflecting updated assumptions for the company’s discount rate, revenue growth outlook and future P/E. The new target is now set at €6.10, compared with the previous €6.10.ナラティブの更新 • Feb 25
IPH: Higher Margin Outlook Will Support Significantly Improved Future Earnings Multiple
Analysts have lifted their price target on Innate Pharma from €4.93 to €6.10, citing updated assumptions for revenue, profit margins and future P/E that together support a higher estimated fair value despite a slightly higher discount rate. Valuation Changes Fair Value: analyst estimate raised from €4.93 to €6.10, representing a sizeable upward revision in the implied share value.ナラティブの更新 • Feb 11
IPH: Updated Assumptions For Discount Rate Will Support Long Term Upside
Analysts have kept their price target for Innate Pharma broadly in line with prior views, with only a marginal adjustment reflecting updated assumptions on the discount rate, revenue growth and future P/E, rather than any major shift in conviction. Valuation Changes Fair Value: Kept unchanged at €6.10, indicating no alteration to the central valuation estimate.ナラティブの更新 • Jan 27
IPH: Upcoming Phase 3 CTCL Trial Will Support Long Term Upside Potential
Analysts have trimmed their price targets for Innate Pharma by a small amount, citing updated assumptions around discount rates, revenue growth, profit margins, and a lower forward P/E, which together indicate a more measured view of the company’s risk and earnings profile. What's in the News The FDA completed its review of Innate Pharma's confirmatory Phase 3 protocol for lacutamab in cutaneous T cell lymphomas, with no further comments, clearing the TELLOMAK 3 trial to proceed (Key Developments).ナラティブの更新 • Jan 12
IPH: Regulatory Progress In Cutaneous T-Cell Lymphomas Will Drive Future Upside
Analysts have raised their price target for Innate Pharma, citing a higher fair value estimate of €6.10 per share compared with the prior €2.49. The revised estimate is supported by updated assumptions around revenue growth, profit margins, discount rate and future P/E.分析記事 • Nov 17
Is Innate Pharma (EPA:IPH) Using Debt In A Risky Way?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...ナラティブの更新 • Sep 18
Clinical Trial Enrollment And FDA Designation Will Open Oncology Opportunities
Analysts have raised Innate Pharma’s price target to €4.93 amid a refocused pipeline and higher risk concentration on antibody-drug conjugates, while cautioning that execution challenges, financing overhang, and lack of partnerships temper near-term confidence. Analyst Commentary Bearish analysts cite Innate Pharma's decision to deprioritize its proprietary antibody-based NK cell engager platform, which they believe overly concentrates the company’s pipeline risk onto its antibody-drug conjugate strategy.分析記事 • Jul 19
Innate Pharma S.A.'s (EPA:IPH) Popularity With Investors Is Under Threat From Overpricing
You may think that with a price-to-sales (or "P/S") ratio of 7.9x Innate Pharma S.A. ( EPA:IPH ) is a stock to avoid...
新しいナラティブ • Apr 04
Clinical Trial Enrollment And FDA Designation Will Open Oncology Opportunities
A robust pipeline of innovative oncology therapeutics and drug candidates highlights strong R&D productivity potentially leading to substantial future earnings.分析記事 • Apr 02
News Flash: Analysts Just Made A Notable Upgrade To Their Innate Pharma S.A. (EPA:IPH) Forecasts
Celebrations may be in order for Innate Pharma S.A. ( EPA:IPH ) shareholders, with the analysts delivering a...分析記事 • Feb 22
Revenues Not Telling The Story For Innate Pharma S.A. (EPA:IPH) After Shares Rise 26%
Innate Pharma S.A. ( EPA:IPH ) shares have continued their recent momentum with a 26% gain in the last month alone. The...分析記事 • Dec 20
Subdued Growth No Barrier To Innate Pharma S.A. (EPA:IPH) With Shares Advancing 37%
Innate Pharma S.A. ( EPA:IPH ) shares have had a really impressive month, gaining 37% after a shaky period beforehand...分析記事 • Oct 24
Risks To Shareholder Returns Are Elevated At These Prices For Innate Pharma S.A. (EPA:IPH)
It's not a stretch to say that Innate Pharma S.A.'s ( EPA:IPH ) price-to-sales (or "P/S") ratio of 4.1x right now seems...分析記事 • May 21
Benign Growth For Innate Pharma S.A. (EPA:IPH) Underpins Its Share Price
You may think that with a price-to-sales (or "P/S") ratio of 3.4x Innate Pharma S.A. ( EPA:IPH ) is definitely a stock...分析記事 • Mar 24
Innate Pharma S.A. (EPA:IPH) Annual Results: Here's What Analysts Are Forecasting For This Year
Innate Pharma S.A. ( EPA:IPH ) just released its latest annual results and things are looking bullish. The results were...分析記事 • Dec 21
Is Innate Pharma (EPA:IPH) Using Debt In A Risky Way?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...分析記事 • Sep 30
Analysts' Revenue Estimates For Innate Pharma S.A. (EPA:IPH) Are Surging Higher
Innate Pharma S.A. ( EPA:IPH ) shareholders will have a reason to smile today, with the analysts making substantial...分析記事 • Sep 16
Some Innate Pharma S.A. (EPA:IPH) Analysts Just Made A Major Cut To Next Year's Estimates
Today is shaping up negative for Innate Pharma S.A. ( EPA:IPH ) shareholders, with the analysts delivering a...分析記事 • Jun 09
Is Innate Pharma (EPA:IPH) Using Debt In A Risky Way?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...株主還元
| IPH | FR Biotechs | FR 市場 | |
|---|---|---|---|
| 7D | 59.6% | -2.4% | 1.5% |
| 1Y | 0.4% | 331.8% | -1.1% |
業界別リターン: IPH過去 1 年間で331.8 % の収益を上げたFrench Biotechs業界を下回りました。
リターン対市場: IPH過去 1 年間で-1.1 % の収益を上げたFrench市場を上回りました。
価格変動
| IPH volatility | |
|---|---|
| IPH Average Weekly Movement | 14.2% |
| Biotechs Industry Average Movement | 9.3% |
| Market Average Movement | 5.4% |
| 10% most volatile stocks in FR Market | 10.7% |
| 10% least volatile stocks in FR Market | 3.0% |
安定した株価: IPHの株価は、 French市場と比較して過去 3 か月間で変動しています。
時間の経過による変動: IPHの 週次ボラティリティ は、過去 1 年間で9%から14%に増加しました。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 1999 | 164 | Jonathan Dickinson | www.innate-pharma.com |
Innate Pharma S.A.は、フランスおよび国際的にがん患者向けの免疫療法を開発するバイオテクノロジー企業として事業を展開している。抗KIR3DL2抗体Lacutamab（IPH4102）は、皮膚T細胞リンパ腫および末梢性T細胞リンパ腫の治療薬として第II相臨床試験中であり、難治性セザリー症候群の治療薬としても第II相臨床試験中である；IPH5201：CD39免疫抑制経路を標的とする第II相臨床試験中のブロック抗体。IPH5301：抗腫瘍免疫を促進する免疫抑制性アデノシン経路を標的とする抗CD73抗体；BCMAを標的とするNK細胞エンゲイジャーIPH6401、CD123を標的とするNKp46ベースのNK細胞エンゲイジャーIPH6101、B7-H3を標的とするNK細胞エンゲイジャーIPH62がある。前臨床試験中の製品は、抗MICA/B ADCのIPH43と抗体薬物複合体（ADC）のIPH45、未発表の多特異性ANKETのIPH67である。同社はアストラゼネカ、ノボノルディスクA/S、サノフィ、オレガバイオテックとライセンス契約および提携契約を結んでおり、メディミューン社とは共同開発およびライセンス契約を結んでいる。Innate Pharma S.A.は1999年に設立され、フランスのマルセイユを拠点としている。
Innate Pharma S.A. 基礎のまとめ
| IPH 基礎統計学 | |
|---|---|
| 時価総額 | €183.91m |
| 収益（TTM） | -€49.18m |
| 売上高(TTM) | €9.01m |
20.4x
P/Sレシオ-3.7x
PER（株価収益率IPH は割高か？
公正価値と評価分析を参照収益と収入
| IPH 損益計算書（TTM） | |
|---|---|
| 収益 | €9.01m |
| 売上原価 | €43.62m |
| 売上総利益 | -€34.61m |
| その他の費用 | €14.56m |
| 収益 | -€49.18m |
直近の収益報告
Dec 31, 2025
次回決算日
Sep 17, 2026
| 一株当たり利益（EPS） | -0.52 |
| グロス・マージン | -384.40% |
| 純利益率 | -546.11% |
| 有利子負債／自己資本比率 | -102.2% |
IPH の長期的なパフォーマンスは？
過去の実績と比較を見る企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/05/20 15:27 |
| 終値 | 2026/05/20 00:00 |
| 収益 | 2025/12/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Innate Pharma S.A. 6 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。13
| アナリスト | 機関 |
|---|---|
| Justin Zelin | BTIG |
| Suranjit Mukherjee | BTIG |
| Yigal Nochomovitz | Citigroup Inc |